1 active not recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Isatuximab SC-OBDS: new trials by email Literature Review of Isatuximab SC-OBDS trials Research Report on Isatuximab SC-OBDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Isatuximab SC-OBDS, Montelukast, Dexamethasone - Plasma Cell Myeloma Refractory | Phase 2 | Active not recruiting | Sanofi | 64 | 2025-03-17 | 2026-10-26 |
Multiple Myeloma (1) · Recurrence (1)
Massachusetts General Hospital (1) · Sanofi (1)
United States (2)
Noopur Raje, MD (1)